[COVID-19, severe asthma, and biologic].

Underner, M; Taillé, C; Peiffer, G; Perriot, J; Jaafari, N

[COVID-19, severe asthma, and biologic]. / COVID-19, asthme sévère et biothérapies.

Underner, M; Taillé, C; Peiffer, G; Perriot, J; Jaafari, N.

Underner M; Unité de Recherche Clinique, Centre Hospitalier Henri Laborit, Université de Poitiers, 370, avenue Jacques CÅur, CS 10587, 86021 Poitiers, France. Electronic address: mike.underner@orange.fr.
Taillé C; AP-HP, Hôpital Bichat, Service de Pneumologie, Centre de référence des maladies pulmonaires rares et Université de Paris, Inserm 1152, 75018 Paris, France.
Peiffer G; Service de pneumologie, CHR Metz-Thionville, 57038 Metz, France.
Perriot J; Dispensaire Emile Roux, Centre de Tabacologie, 63100 Clermont-Ferrand, France.
Jaafari N; Unité de Recherche Clinique, Centre Hospitalier Henri Laborit, Université de Poitiers, 370, avenue Jacques CÅur, CS 10587, 86021 Poitiers, France.

Rev Mal Respir ; 38(4): 423-426, 2021 04.

Article in French | MEDLINE | ID: covidwho-1155621

Subject(s)

Anti-Asthmatic Agents/therapeutic use; Asthma/complications; Asthma/drug therapy; Biological Therapy; COVID-19/complications; Angiotensin-Converting Enzyme 2/metabolism; Humans; Respiratory Mucosa/metabolism; Self Administration

Keywords

Asthme sévère; Biologic; Biothérapies; COVID-19; SARS-CoV-2; Severe asthma

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Asthma / Biological Therapy / Anti-Asthmatic Agents / COVID-19 Topics: Long Covid Limits: Humans Language: French Journal: Rev Mal Respir Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google